PMID: 43552Jan 1, 1979

Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine

M D AllenJ D Arnold


The pharmacokinetic properties of estazolam, a triazolo benzodiazepine hypnotic agent, were assessed in a series of healthy volunteers following single and multiple doses. After single oral doses of 2--16 mg, peak plasma concentrations were reached within 6 h. Values of elimination half-life ranged from 8.3--31.2 h (mean 17.0 h) and did not vary significantly with dose. During 3 weeks of therapy, steady-state plasma concentrations increased approximately in proportion to increasing doses. and accumulation was essentially complete within 3 days of each dose change. The mean observed accumulation ratio was 1.84, which was slightly larger than the predicted ratio of 1.53. Exposure to multiple-dose estazolam therapy had no significant influence on the kinetics of a single dose of antipyrine, suggesting that estazolam neither stimulates nor inhibits enzyme activity in humans. Thus the accumulation and elimination kinetics of estazolam can be classified as intermediate to those of the short-acting (such as oxazepam) and the long-acting (such as diazepam) benzodiazepine derivatives.


Aug 1, 1978·Southern Medical Journal·D J Greenblatt, R I Shader
Jan 1, 1979·Journal of Pharmaceutical Sciences·D J GreenblattE Woo
Jan 1, 1979·Annual Review of Pharmacology and Toxicology·D J Greenblatt
Aug 1, 1975·The Journal of Infectious Diseases·M BarzaL Weinstein
Jun 1, 1975·Journal of Pharmacokinetics and Biopharmaceutics·K S AlbertJ G Wagner
Oct 2, 1975·The New England Journal of Medicine·D J Greenblatt, J Kock-Weser
Aug 1, 1975·Journal of Pharmacokinetics and Biopharmaceutics·T J Benya, J G Wagner
Nov 7, 1974·The New England Journal of Medicine·D J Greenblatt, R I Shader
Dec 5, 1974·The New England Journal of Medicine·D J Greenblatt, R I Shader
Apr 1, 1974·Journal of Pharmacokinetics and Biopharmaceutics·H G BoxenbaumR M Elashoff
Jan 1, 1970·Journal of Pharmaceutical Sciences·J C Loo, S Riegelman
Apr 1, 1979·Journal of Pharmacokinetics and Biopharmaceutics·D J GreenblattR I Shader


Jun 1, 1990·Journal of Clinical Pharmacology·J B SkatrudD Juan
Aug 1, 1991·Journal of Clinical Pharmacology·J B CohnM Ettinger
Mar 1, 1987·Pharmacology, Biochemistry, and Behavior·C E Johanson
Nov 17, 1993·Journal of Chromatography·J F Kelly, D J Greenblatt
May 31, 2002·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Masatomo MiuraKoichi Otani
Jan 1, 1983·Drug Metabolism Reviews·D J GreenblattR I Shader
Jan 1, 1984·Current Medical Research and Opinion·R Jochemsen, D D Breimer
Mar 2, 1990·The American Journal of Medicine·D J GreenblattR I Shader
Mar 2, 1990·The American Journal of Medicine·L E Gustavson, P J Carrigan
Mar 1, 1985·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A MancinelliS Caccia
Apr 1, 1997·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·L Dal BoM L De Vito
Mar 1, 1983·Klinische Wochenschrift·H R Ochs
Mar 1, 1997·Journal of Anesthesia·Yuichi Kanmura, Mutumi Kamihashi
Jan 1, 1986·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J M MachinistD Rollins
Jan 1, 1981·British Journal of Clinical Pharmacology·D J GreenblattJ S Harmatz

Related Concepts

Intestinal Absorption
Anti-Anxiety Effect

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.